[go: up one dir, main page]

NO996117L - Anordning for tilfoering av medikamenter samt behandling av virale og mikrobielle infeksjoner og taeringssyndrom - Google Patents

Anordning for tilfoering av medikamenter samt behandling av virale og mikrobielle infeksjoner og taeringssyndrom

Info

Publication number
NO996117L
NO996117L NO996117A NO996117A NO996117L NO 996117 L NO996117 L NO 996117L NO 996117 A NO996117 A NO 996117A NO 996117 A NO996117 A NO 996117A NO 996117 L NO996117 L NO 996117L
Authority
NO
Norway
Prior art keywords
microbial infections
syndrome
taering
treating viral
administering medications
Prior art date
Application number
NO996117A
Other languages
English (en)
Other versions
NO996117D0 (no
Inventor
Michelle Olga Patricia Visser
Original Assignee
Cryopreservation Tech Cc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/874,425 external-priority patent/US5935597A/en
Application filed by Cryopreservation Tech Cc filed Critical Cryopreservation Tech Cc
Publication of NO996117D0 publication Critical patent/NO996117D0/no
Publication of NO996117L publication Critical patent/NO996117L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Nye medikamentavleveringsanordninger, fremgangsmåter og terapeutiske sammensetninger er beskrevet for behandling av virale og mikrobielle infeksjoner og tæringssyndrom i dyr, innbefattende mennesker. Det er beskrevet å administrere til en pasient i behov for behandling en polar forbindelse så som dimetylformamid eller dimetylsulfoksid, fortrinnsvis via en transdermal rute. Det er videre beskrevet en vaksine fremstilt fra antistoff innhøstet fra legemet hos en pasi- ent behandlet ved fremgangsmåten for en viral infeksjon.
NO996117A 1997-06-13 1999-12-10 Anordning for tilfoering av medikamenter samt behandling av virale og mikrobielle infeksjoner og taeringssyndrom NO996117L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/874,425 US5935597A (en) 1995-12-15 1997-06-13 Drug delivery devices and methods for treatment of viral and microbial infections and wasting syndromes
PCT/US1998/011956 WO1998056325A1 (en) 1997-06-13 1998-06-09 Drug delivery devices and methods for treatment of viral and microbial infections and wasting syndromes

Publications (2)

Publication Number Publication Date
NO996117D0 NO996117D0 (no) 1999-12-10
NO996117L true NO996117L (no) 2000-02-11

Family

ID=25363728

Family Applications (1)

Application Number Title Priority Date Filing Date
NO996117A NO996117L (no) 1997-06-13 1999-12-10 Anordning for tilfoering av medikamenter samt behandling av virale og mikrobielle infeksjoner og taeringssyndrom

Country Status (34)

Country Link
EP (1) EP1011567A1 (no)
JP (1) JP4531141B2 (no)
KR (1) KR20010013709A (no)
CN (1) CN1260703A (no)
AP (1) AP1629A (no)
AR (1) AR012970A1 (no)
AU (1) AU7831598A (no)
BG (1) BG103997A (no)
BR (1) BR9810095A (no)
CA (1) CA2295176A1 (no)
CZ (1) CZ298510B6 (no)
EA (1) EA200000011A1 (no)
EE (1) EE9900562A (no)
ES (1) ES2161187B1 (no)
FI (1) FI19992648L (no)
GB (1) GB2341319B (no)
HU (1) HUP0003034A2 (no)
ID (1) ID23516A (no)
IL (2) IL133396A0 (no)
IS (1) IS5289A (no)
LT (1) LT4714B (no)
LV (1) LV12490B (no)
NO (1) NO996117L (no)
NZ (1) NZ501669A (no)
OA (1) OA11307A (no)
PL (1) PL196256B1 (no)
RO (1) RO121252B1 (no)
SI (1) SI20191A (no)
SK (1) SK172299A3 (no)
TN (1) TNSN98086A1 (no)
TR (1) TR200000540T2 (no)
WO (1) WO1998056325A1 (no)
YU (1) YU66099A (no)
ZA (1) ZA984649B (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005004729A1 (en) * 2003-06-30 2005-01-20 Alza Corporation Method for coating skin piercing microprojections
AP2006003648A0 (en) * 2003-12-05 2006-06-30 Namibia Medical Invest Pty Ltd Patch

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE60941B1 (en) * 1986-07-10 1994-09-07 Elan Transdermal Ltd Transdermal drug delivery device
US4855294A (en) * 1988-09-06 1989-08-08 Theratech, Inc. Method for reducing skin irritation associated with drug/penetration enhancer compositions
US5534260A (en) * 1989-02-23 1996-07-09 University Of Utah Percutaneous drug delivery system
US5028435A (en) * 1989-05-22 1991-07-02 Advanced Polymer Systems, Inc. System and method for transdermal drug delivery
US5624912A (en) * 1991-08-21 1997-04-29 Burcoglu; Arsinur Method of treating HIV infection and related secondary infections with defibrotide
NZ249032A (en) * 1992-02-20 1996-09-25 Merrell Dow Pharma Stilbene disulphonic acid derivatives substituted in the 4- and 4'-positions by thioureido, thiocarbonate ester, and thiocarbamate and thiocarbamoyloxy (and -omino) and thioamide groups; use in treating viral diseases
IL124733A0 (en) * 1995-12-15 1999-01-26 Cryopreservation Tech Cc Composition for organ cryopreservation and treatment of viral and bacterial infections

Also Published As

Publication number Publication date
TR200000540T2 (tr) 2000-09-21
EA200000011A1 (ru) 2000-08-28
AR012970A1 (es) 2000-11-22
NO996117D0 (no) 1999-12-10
IL133396A0 (en) 2001-04-30
ID23516A (id) 2000-04-27
BR9810095A (pt) 2001-11-13
IL133396A (en) 2006-10-05
SI20191A (sl) 2000-10-31
AU7831598A (en) 1998-12-30
KR20010013709A (ko) 2001-02-26
LT99148A (lt) 2000-07-25
PL196256B1 (pl) 2007-12-31
EP1011567A4 (en) 2000-06-28
JP2002511862A (ja) 2002-04-16
CZ9904473A3 (cs) 2001-03-14
LV12490B (en) 2000-12-20
IS5289A (is) 1999-12-08
ZA984649B (en) 1999-12-17
WO1998056325A1 (en) 1998-12-17
FI19992648A7 (fi) 2000-02-03
YU66099A (sh) 2002-10-18
AP9901708A0 (en) 1999-12-31
LT4714B (lt) 2000-10-25
EP1011567A1 (en) 2000-06-28
EE9900562A (et) 2000-06-15
ES2161187B1 (es) 2003-08-16
CA2295176A1 (en) 1998-12-17
BG103997A (bg) 2001-07-31
NZ501669A (en) 2001-09-28
GB2341319B (en) 2002-02-27
TNSN98086A1 (fr) 2005-03-15
GB2341319A (en) 2000-03-15
OA11307A (en) 2003-10-24
RO121252B1 (ro) 2007-02-28
JP4531141B2 (ja) 2010-08-25
PL338439A1 (en) 2000-11-06
GB9929189D0 (en) 2000-02-02
CN1260703A (zh) 2000-07-19
HUP0003034A2 (hu) 2000-12-28
SK172299A3 (en) 2000-09-12
ES2161187A1 (es) 2001-11-16
FI19992648L (fi) 2000-02-03
AP1629A (en) 2006-07-11
LV12490A (en) 2000-06-20
CZ298510B6 (cs) 2007-10-24

Similar Documents

Publication Publication Date Title
DK1151009T3 (da) Antimikrobielt/endotoksin-neutraliserende polypeptid
JP6382798B2 (ja) 局所非水性医薬製剤
KR910700048A (ko) 오메프라졸의 항균제로서의 용도
DE60331537D1 (de) Kombinationen zur behandlung von multiplem myelom
CY1116464T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
DE69433901D1 (de) Verbindungen und pharmazeutische zusammensetzungen zur behandlung und prophylaxe bakterieller infektionen
CY1107452T1 (el) Διαδερμικη μορφη χορηγησης για τη θεραπεια του συνδρομου ανησυχων ποδιων
WO2005009961B1 (en) Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
NO20061325L (no) Kombinasjon av legemidler for behandling av neoplasmer
ATE399562T1 (de) Verwendung von milchserum-apoproteinen bei der prophylaxe oder behandlung von mikrobiellen oder virusinfektionen
Inanmaz et al. Extracorporeal shockwave increases the effectiveness of systemic antibiotic treatment in implant‐related chronic osteomyelitis: experimental study in a rat model
BR0206869A (pt) método para o tratamento de um animal sofrendo de um estado doentio de disfunção imune associado com nìveis alterados de igg ou tnf-delta, composição farmacêutica para o tratamento de distúrbios auto-imunes associados com elevados igg e/ou tnf-delta ou para a potenciação de protocolos de vacina, e método para o tratamento de estado doentio associado com disfunção imune em um animal
DE60331412D1 (de) Hiv-vakzine und anwendungsverfahren
DE60018409D1 (de) Verwendung von antiseptika zur herstelllung von arzneimitteln zur prophylaxe und behandlung von infektionen und/ oder funktionellen gewebeumformungen im körperinneren
DE69929616D1 (de) Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
NO996117L (no) Anordning for tilfoering av medikamenter samt behandling av virale og mikrobielle infeksjoner og taeringssyndrom
BRPI0412924A (pt) tratamento pré-operatório de dor pós-operatória
DK0559145T3 (da) Lægemiddel til truende abort
SE9700244D0 (sv) Novel antibacterial protein
PT1156795E (pt) Utilizacao de acido succinico ou de seus sais e metodo de tratamento da resistencia a insulina
ATE230264T1 (de) Medizinische zusammensetzungen gegen helicobacter pylori
CY1105545T1 (el) Θεραπεια στατινης για ενισχυση της διατηρησης νοητικης λειτουργιας
NO20006161D0 (no) Topisk tilförsel av oksazolidinoner for transdermal levering
DE50214008D1 (de) Arzneimittel zur behandlung von tumoren und deren metastasen unter verwendung eines bindemoleküls gegen das bone-sialoprotein
BR0316123A (pt) Formulação farmacêutica aquosa, uso de uma formulação farmacêutica aquosa, e, método de tratamento de um paciente com necessidade de tratamento antitrombótico

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application